LENZ (LENZ Therapeutics) 3-Year RORE % : -19.51% (As of Mar. 2026)


LENZ LENZ Therapeutics Inc LENZ
12 GF Score
Price $5.59
! 2 Warning Signs
View Full Analysis

What is LENZ Therapeutics 3-Year RORE %?

LENZ Therapeutics LENZ -3.45% 12 3-Year RORE % is -19.51 as of Mar. 2026. GuruFocus rates LENZ with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 1,289 Biotechnology companies, LENZ Therapeutics ranks worse than 58.49% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. LENZ Therapeutics's 3-Year RORE % for the quarter that ended in Mar. 2026 was -19.51%.

The industry rank for LENZ Therapeutics's 3-Year RORE % or its related term are showing as below:

LENZ's 3-Year RORE % is ranked worse than
58.49% of 1289 companies
in the Biotechnology industry
Industry Median: -11.44 vs LENZ: -19.51

LENZ Therapeutics  (NAS:LENZ) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


LENZ Therapeutics 3-Year RORE % Related Terms


LENZ Therapeutics 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for LENZ Therapeutics's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LENZ Therapeutics 3-Year RORE % Chart

LENZ Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
0.00 0.00 0.00 0.00 0.68

LENZ Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 5.12 -0.75 0.68 -19.51

LENZ vs KRRO, ANTX, OKUR: 3-Year RORE % Comparison

For the Biotechnology subindustry, LENZ Therapeutics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LENZ Therapeutics 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LENZ Therapeutics's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where LENZ Therapeutics's 3-Year RORE % falls into.


LENZ
12GF Score
LENZ Therapeutics Inc LENZ
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LENZ Therapeutics 3-Year RORE % Calculation

LENZ Therapeutics's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -3.6--5.774 )/( -11.144-0 )
=2.174/-11.144
=-19.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -19.51 mean?
LENZ Therapeutics (LENZ) has a 3-Year RORE % of -19.51 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on LENZ Therapeutics and its competitors. According to the industry distribution chart, LENZ Therapeutics ranks #754 out of 1289 companies in the Biotechnology industry, placing it in the top 58.5%.
Is LENZ Therapeutics' 3-Year RORE % too high?
LENZ Therapeutics' current 3-Year RORE % is -19.51. Based on the distribution chart, LENZ Therapeutics ranks #754 out of 1289 companies in the Biotechnology industry, which is below the industry midpoint. Overall, LENZ Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LENZ Therapeutics' 3-Year RORE % compare to KRRO and ANTX?
According to the Biotechnology industry distribution chart, LENZ Therapeutics ranks #754 out of 1289 companies for 3-Year RORE %. This places LENZ Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on LENZ Therapeutics and its competitors. LENZ Therapeutics's current 3-Year RORE % is -19.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LENZ Therapeutics stock overvalued right now?
LENZ Therapeutics (LENZ) has a current 3-Year RORE % of -19.51. The current 3-Year RORE % is -19.51. LENZ Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For LENZ Therapeutics (LENZ), the current 3-Year RORE % is -19.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LENZ Therapeutics Business Description

Address 201 Lomas Santa Fe Drive, Suite 300, Solana Beach, CA, USA, 92075
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
12GF Score

Get the complete analysis for LENZ

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.59
Price